A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

We report the results of a Phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed/refractory acute leukemias using an intermittent dosing regimen. Fifteen patients with advanced leukemia (Acute myeloid leukemia(AML), 2=Acute lymphoblastic leukemia(ALL), 1 Biphenotypic) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratz, Keith W., Cho, Eunpi, Levis, Mark J., Karp, Judith E., Gore, Steven D., McDevitt, Michael, Stine, Adam, Zhao, Ming, Baker, Sharyn D., Carducci, Michael A., Wright, John J., Rudek, Michelle A., Smith, B. Douglas
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921005/
https://www.ncbi.nlm.nih.gov/pubmed/20535150
http://dx.doi.org/10.1038/leu.2010.132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921005/
https://www.ncbi.nlm.nih.gov/pubmed/20535150
http://dx.doi.org/10.1038/leu.2010.132

Ejemplares similares